Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
3(50.0%)
Phase 1
3(50.0%)
6Total
Phase 2(3)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07528053Phase 1Not Yet Recruiting

A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy Participants

Role: lead

NCT06846398Phase 2Active Not Recruiting

A Phase 2 in Adult Subjects With Hereditary Angioedema

Role: lead

NCT07401472Phase 1Recruiting

Study of BW-50218 in Healthy Participants

Role: lead

NCT07135349Phase 2Active Not Recruiting

A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B

Role: lead

NCT06497127Phase 2Active Not Recruiting

A Study in Patients With Mixed Dyslipidemia

Role: lead

NCT06917482Phase 1Recruiting

A Study to Assess the Safety and Effects of the Investigational Drug BW-40202 in Healthy Volunteers

Role: lead

All 6 trials loaded